NASDAQ:VTVT vTv Therapeutics (VTVT) Stock Price, News & Analysis → Has Trump Finally Gone Too Far? (From Insiders Exposed) (Ad) Free VTVT Stock Alerts $21.02 -1.79 (-7.85%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$21.02▼$24.0050-Day Range$17.10▼$29.0152-Week Range$7.38▼$34.00Volume4,070 shsAverage Volume4,670 shsMarket Capitalization$63.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get vTv Therapeutics alerts: Email Address Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About vTv Therapeutics Stock (NASDAQ:VTVT)vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.Read More VTVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VTVT Stock News HeadlinesJune 15 at 6:54 AM | americanbankingnews.comShort Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Declines By 21.8%May 28, 2024 | prnewswire.comCANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETINGMay 27, 2024 | finance.yahoo.comShareholders in vTv Therapeutics (NASDAQ:VTVT) are in the red if they invested three years agoMay 11, 2024 | finanznachrichten.devTv Therapeutics Inc.: vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate UpdateMay 10, 2024 | investorplace.comVTVT Stock Earnings: vTv Therapeutics Reported Results for Q1 2024May 9, 2024 | globenewswire.comvTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate UpdateMarch 19, 2024 | finance.yahoo.comCANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITMarch 13, 2024 | finanznachrichten.devTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateMarch 13, 2024 | globenewswire.comvTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateMarch 6, 2024 | investing.comvTv Therapeutics starts phase 3 trial for diabetes drugMarch 4, 2024 | investorplace.comThe Top 3 Healthcare Stocks to Buy on Weakness in 2024March 4, 2024 | globenewswire.comvTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 DiabetesMarch 1, 2024 | globenewswire.comvTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare ConferenceFebruary 29, 2024 | bizjournals.comvTv Therapeutics' stock doubles after raising $51 million from health care investors including JDRFFebruary 28, 2024 | msn.comWhy Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today?February 28, 2024 | finance.yahoo.comvTv Therapeutics Inc. (VTVT)February 28, 2024 | markets.businessinsider.comNasdaq Down 50 Points; US Crude Stocks Rise By 4.2M BarrelsFebruary 28, 2024 | marketwatch.comVTv Therapeutics Shares Surge on $51 Million Private PlacementFebruary 28, 2024 | wsj.comvTv Therapeutics Inc. Cl AFebruary 28, 2024 | finance.yahoo.comvTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundFebruary 28, 2024 | globenewswire.comvTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundFebruary 22, 2024 | prnewswire.comCANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCEJanuary 31, 2024 | uk.investing.comvTv Therapeutics Inc (VTVT)November 27, 2023 | money.usnews.comvTv Therapeutics Inc - Ordinary Shares - Class ANovember 21, 2023 | bizjournals.comvTv Therapeutics regains compliance with Nasdaq after 1-for-40 reverse stock splitSee More Headlines Receive VTVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/15/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VTVT CUSIPN/A CIK1641489 Webwww.vtvtherapeutics.com Phone(336) 841-0300Fax336-841-0310Employees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($8.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,250,000.00 Net MarginsN/A Pretax Margin-2,611.10% Return on EquityN/A Return on Assets-80.41% Debt Debt-to-Equity RatioN/A Current Ratio6.04 Quick Ratio6.04 Sales & Book Value Annual Sales$2.02 million Price / Sales31.32 Cash FlowN/A Price / Cash FlowN/A Book Value($9.27) per share Price / Book-2.27Miscellaneous Outstanding Shares3,010,000Free Float2,970,000Market Cap$63.27 million OptionableNot Optionable Beta0.60 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Paul J. Sekhri M.Sc. (Age 66)CEO, President & Chairman of the Board Comp: $650.91kMr. Steven Tuch M.B.A. (Age 55)Executive VP & CFO Comp: $465.25kDr. Carmen Valcarce Ph.D.Chief Scientific Officer & Executive VPMs. Elizabeth M. Keiley (Age 58)Executive VP & General Counsel Mr. Richard S. Nelson (Age 54)Executive VP of Corporate Development & Director Comp: $201.08kDr. Thomas Strack M.D.Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsEnochian BiosciencesNASDAQ:ENOBAclaris TherapeuticsNASDAQ:ACRSLumos PharmaNASDAQ:LUMORenovaroNASDAQ:RENBRezoluteNASDAQ:RZLTView All CompetitorsInstitutional OwnershipBaker BROS. Advisors LPBought 97,314 shares on 5/15/2024Ownership: 3.233%View All Institutional Transactions VTVT Stock Analysis - Frequently Asked Questions How have VTVT shares performed in 2024? vTv Therapeutics' stock was trading at $11.50 at the beginning of the year. Since then, VTVT stock has increased by 82.8% and is now trading at $21.02. View the best growth stocks for 2024 here. Are investors shorting vTv Therapeutics? vTv Therapeutics saw a decrease in short interest in May. As of May 31st, there was short interest totaling 18,600 shares, a decrease of 21.8% from the May 15th total of 23,800 shares. Based on an average trading volume of 10,200 shares, the short-interest ratio is presently 1.8 days. Currently, 1.4% of the company's stock are short sold. View vTv Therapeutics' Short Interest. When is vTv Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our VTVT earnings forecast. How were vTv Therapeutics' earnings last quarter? vTv Therapeutics Inc. (NASDAQ:VTVT) issued its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($1.17) EPS for the quarter. The biotechnology company had revenue of $1 million for the quarter. When did vTv Therapeutics' stock split? Shares of vTv Therapeutics reverse split on Tuesday, November 21st 2023. The 1-40 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of vTv Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA). When did vTv Therapeutics IPO? vTv Therapeutics (VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers. Who are vTv Therapeutics' major shareholders? vTv Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (3.23%). Insiders that own company stock include John A Fry and Ronald O Perelman. View institutional ownership trends. How do I buy shares of vTv Therapeutics? Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VTVT) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share vTv Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.